NDAORALTABLET1 Generic Approved
Approved
Nov 2000
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Clinical Trials
2
Data completeness
4/8 — Partial
MICARDIS HCT (telmisartan and hydrochlorothiazide) by Boehringer Ingelheim is angiotensin 2 receptor antagonists [moa]. First approved in 2000.
Drug data last refreshed 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MICARDIS HCT is a fixed-dose combination tablet containing telmisartan (an angiotensin II receptor antagonist) and hydrochlorothiazide (a thiazide diuretic) for oral treatment of hypertension. It works by blocking angiotensin II receptors to relax blood vessels while simultaneously promoting sodium and water excretion to reduce blood volume. This dual mechanism provides additive antihypertensive effects in a single daily dose.
$0.947MPart D
LOE ApproachingDeclining
As LOE approaches, the MICARDIS HCT commercial team is likely consolidating and shifting focus to existing patient retention and managed care contracting rather than growth initiatives.
Mechanism of Action
Angiotensin 2 Receptor Antagonists
Pharmacologic Class:
Thiazide Diuretic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Pharmaco-epidemiological Study Describing a Population of Hypertensive Patients Treated With a Fixed-dose Combination of Telmisartan and Hydrochlorothiazide
Started Apr 2006
4,255 enrolled
Hypertension
3 x 3 Factorial Trial of Telmisartan and Hydrochlorothiazide in Patients With Essential Hypertension
Started Jun 2004
583 enrolled
Hypertension
Career Relevance
MICARDIS HCT currently shows zero linked job postings, reflecting its mature lifecycle and declining commercial priority at Boehringer Ingelheim. Career opportunities on this product are minimal and concentrated in field force and managed care roles rather than strategic or clinical functions.
Worked on MICARDIS HCT at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.